Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States-Reference-Cited by-同舟云学术

Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

Published:2018-09 Issue:9 Volume:11 Page:
ISSN:1941-3289
Container-title:Circulation: Heart Failure
language:en
Short-container-title:Circ Heart Fail

Author:

DeVore Adam D.¹²,Hill C. Larry¹,Thomas Laine¹,Sharma Puza P.³,Albert Nancy M.⁴,Butler Javed⁵,Patterson J. Herbert⁶,Spertus John A.⁷,Williams Fredonia B.⁸,Duffy Carol I.³,McCague Kevin³,Hernandez Adrian F.¹²,Fonarow Gregg C.⁹

Affiliation:

1. Duke Clinical Research Institute, Durham, NC (A.D.D., C.L.H., L.T., A.F.H.).

2. Department of Medicine, Duke University School of Medicine, Durham, NC (A.D.D., A.F.H.).

3. Novartis Pharmaceuticals Corporation, East Hanover, NJ (P.P.S., C.I.D., K.M.).

4. Cleveland Clinic, OH (N.M.A.).

5. University of Mississippi Medical Center, Jackson (J.B.).

6. Eshelman School of Pharmacy, University of North Carolina, Chapel Hill (J.H.P.).

7. Saint Luke’s Mid America Heart Institute and the University of Missouri-Kansas City (J.A.S.).

8. Mended Hearts, Huntsville, AL (F.B.W.).

9. Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center (G.C.F.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference14 articles.

1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

2. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

3. Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure

4. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction

5. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Initiative Increasing GDMT Use Among Patients With Heart Failure With Reduced Ejection Fraction;JACC: Heart Failure;2024-08

2. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia;Medicine;2023-12-22

3. A machine learning evaluation of patient characteristics associated with prescribing of guideline-directed medical therapy for heart failure;Frontiers in Cardiovascular Medicine;2023-06-21

4. Clinician challenges to evidence‐based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation;Journal of Evaluation in Clinical Practice;2023-06-19

5. Modern approaches to interpretation of clinical trial results to evaluate the effectiveness of heart failure therapy. Analysis of the results of randomized trials PARADIGM-HF, DAPA-HF, EMPEROR-Reduced and VICTORIA;Russian Journal of Cardiology;2023-04-07